Who are Androgen receptor targeted therapy's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/androgen-receptor-targeted-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Androgen receptor targeted therapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Androgen receptor targeted therapy (Androgen receptor targeted therapy) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Androgen receptor antagonist or modulator. Area: Oncology.

phase 3 Androgen receptor antagonist or modulator Androgen receptor (AR) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Androgen receptor targeted therapy (Androgen receptor targeted therapy) — Universitaire Ziekenhuizen KU Leuven. This therapy targets the androgen receptor to modulate hormone-dependent signaling pathways, typically used in hormone-sensitive cancers.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Androgen receptor targeted therapy TARGET	Androgen receptor targeted therapy	Universitaire Ziekenhuizen KU Leuven	phase 3	Androgen receptor antagonist or modulator	Androgen receptor (AR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Androgen receptor antagonist or modulator class)

Universitaire Ziekenhuizen KU Leuven · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Androgen receptor targeted therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/androgen-receptor-targeted-therapy. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab